UBS lifts target for Quest Diagnostics stock to USD 250.00

Published on 10/20/2026 at 21:38 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

UBS keeps Neutral and lifts its target to USD 250.00 on October 19, 2026. Quest Diagnostics stock costs EUR 210.30 on October 20, 2026.

Analyst target and results date

UBS raised its Quest Diagnostics target from USD 245.00 to USD 250.00 on October 19, 2026.
Quest Diagnostics is scheduled to report third-quarter 2026 results on October 22, 2026.
Quest Diagnostics stock costs EUR 210.30 at Lang & Schwarz on October 20, 2026 at 9:34 p.m. CEST.

Automatisierter Laboranalysator mit Blutproben-Röhrchen in klinischem Diagnostiklabor — Quest Diagnostics US74834L1008 zeigt automatisierten Laboranalysator mit Blutproben in modernem Diagnostiklabor fotorealistisch dargestellt, Illustration mit AI erstellt.

Quest Diagnostics raised its investor focus ahead of its next results after UBS lifted the price target from USD 245.00 to USD 250.00 on October 19, 2026, while keeping a Neutral rating, according to Markets Insider. Quest Diagnostics stock was trading at EUR 210.30 at Lang & Schwarz on October 20, 2026 at 9:34 p.m. CEST.

UBS target leaves measured upside

The UBS target implies 5.89 percent upside from the NYSE price of USD 236.10 at 3:37 p.m. ET on October 20, 2026. The target therefore sits above the latest US quotation while the Neutral rating signals a more restrained view of the valuation.

Quest Diagnostics remains near its yearly high

The stock traded between USD 171.18 and USD 248.84 over the 52-week period through October 20, 2026. At USD 236.10, it stood 5.10 percent below the 52-week high and 37.92 percent above the 52-week low. Quest Diagnostics had a market capitalization of USD 26.1 billion and a price-to-earnings ratio of 25.06 on that date.

What does the target imply?

The target update arrives before the company reports third-quarter 2026 results. Quest Diagnostics announced on September 22, 2026 that the release would come before the market opens on October 22, 2026, with the conference call scheduled for 8:30 a.m. ET, according to Quest Diagnostics. The timing makes the upcoming report the next concrete test for the analyst view.

Diagnostics scale supports the setup

Quest Diagnostics operates a nationwide diagnostic testing network with more than 2,000 locations and performs more than 200 million tests each year, according to its corporate site. Its healthcare diagnostics business serves patients, physicians, hospitals, health plans and employers through routine and advanced testing services.

Stock price and next date

The euro quotation was EUR 210.30 at Lang & Schwarz on October 20, 2026 at 9:34 p.m. CEST. The next scheduled corporate event is Quest Diagnostics' third-quarter 2026 results release on October 22, 2026 before the US market opens. The further course of trading is shown by the continuously updated real-time quote of Quest Diagnostics stock.